drug
doxycycline ER
Marketedupdated 4mo agoby Prasco LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval340 co-mentions · 170 sources
- drugDOXYCYCLINE173 co-mentions · 173 sources
- drugVibramycin173 co-mentions · 173 sources
- drugDrug for Unspecified Dermatological Disorders173 co-mentions · 173 sources
- tagSmall Molecule168 co-mentions · 168 sources
- drugdoxycycline hyclate CR109 co-mentions · 109 sources
- drugDoryx109 co-mentions · 109 sources
- drugdoxycycline hyclate DR109 co-mentions · 109 sources
all catalysts(39)
approval · 38
Dec 1, 2000
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Dec 15, 2000
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Oct 17, 2001
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Feb 26, 2002
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Dec 19, 2002
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Dec 30, 2002
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Dec 30, 2002
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
May 21, 2003
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Feb 20, 2004
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Mar 26, 2004
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Apr 15, 2005
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Apr 18, 2005
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Apr 18, 2005
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Jul 14, 2005
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Jul 14, 2005
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Jul 15, 2005
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Aug 1, 2005
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Mar 12, 2009
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Mar 12, 2009
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Apr 18, 2012
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Dec 14, 2012
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
May 31, 2013
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Jul 10, 2014
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Sep 26, 2014
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Dec 20, 2015
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Dec 20, 2015
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Sep 23, 2016
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Oct 30, 2017
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Aug 30, 2022
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Aug 30, 2022
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Aug 26, 2024
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Aug 26, 2024
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Aug 26, 2024
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Aug 26, 2024
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Aug 26, 2024
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Oct 1, 2025
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Mar 11, 2026
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Mar 20, 2026
approval
DOXYCYCLINE — FDA approval
doxycycline ER
→
Trials studying doxycycline ER
- phase2Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway
- phase2Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
- —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- phase4Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.
- phase1Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
- phase2Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
- phase2Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
- phase3A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 19, 2027
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Dec 19, 2027formulationUS 77495321.3y
News(1)
- Syphilis spreads while researchers contend with federal constraints and a drug shortageAt the San Diego-Tijuana border, syphilis spreads while researchers contend with federal constraints and a drug shortage.stat · 1mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that